Welcome to the international HTA database

Showing [16386 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	NIHR Public Health Research (PHR) programme	Change in alcohol outlet density and alcohol-related harm to population health (CHALICE): a comprehensive record-linked database study in Wales
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - Hodgkin lymphoma: classical; relapsed or refractory – third and fourth line
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab in combination with ipilimumab for treating advanced melanoma. NICE technology appraisal guidance 400
2016	NIHR Health Technology Assessment programme	EQUATOR Network
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Quizartinib - acute myeloid leukaemia: relapsed or refractory; FLT3-internal tandem duplication (ITD) positive – second line
2016	National Institute for Health and Care Excellence (NICE)	Bosutinib for previously treated chronic myeloid leukaemia. NICE technology appraisal guidance 401
2016	NIHR Health Technology Assessment programme	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib with tamoxifen and goserelin, or a non-steroidal aromatase inhibitor and goserelin - breast cancer: advanced; hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative; premenopausal women – first line
2016	National Institute for Health and Care Excellence (NICE)	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016	NIHR Health Technology Assessment programme	Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Sapacitabine - acute myeloid leukaemia: patients ≥70 years of age; not candidates for standard intensive therapy – first line
2016	National Institute for Health and Care Excellence (NICE)	Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016	NIHR Health Technology Assessment programme	Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Zoptarelin doxorubicin - endometrial cancer: locally advanced, recurrent or metastatic – second line
2016	National Institute for Health and Care Excellence (NICE)	Degarelix for treating advanced hormone-dependent prostate cancer. NICE technology appraisal guidance 404
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Volanesorsen - familial chylomicronemia syndrome – first line
2016	National Institute for Health and Care Excellence (NICE)	Trifluridine-tipiracil for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 405
2016	NIHR Health Technology Assessment programme	A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Simtuzumab - liver fibrosis secondary to non-alcoholic steatohepatitis or primary sclerosing cholangitis
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Teduglutide (Revestive) - short bowel syndrome: in paediatric patients aged 1-17 years who are dependent on parenteral nutrition
2016	National Institute for Health and Care Excellence (NICE)	Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors. NICE technology appraisal guidance 407
2016	NIHR Health Technology Assessment programme	A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial
2016	NIHR Health Services and Delivery Research programme	Management by geographical area or management specialised by disorder? A mixed-methods evaluation of the effects of an organisational intervention on secondary mental health care for common mental disorder
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Begelomab (Begesand) - graft versus host disease: acute; steroid resistant – second line
2016	National Institute for Health and Care Excellence (NICE)	Pegaspargase for treating acute lymphoblastic leukaemia. NICE technology appraisal guidance 408
2016	NIHR Health Technology Assessment programme	An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Caplacizumab-Thrombotic thrombocytopenic purpura: acquired; acute phase – adjunctive therapy
2016	National Institute for Health and Care Excellence (NICE)	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. NICE technology appraisal guidance 409
2016	NIHR Health Technology Assessment programme	BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial
2016	Agency for Healthcare Research and Quality (AHRQ)	Noninvasive testing for coronary artery disease
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Relebactam with imipenem and cilastatin - multi-drug resistant or carbapenem resistant Gram-negative infections
2016	National Institute for Health and Care Excellence (NICE)	Talimogene laherparepvec for treating unresectable metastatic melanoma. NICE technology appraisal guidance 410
2016	Agency for Healthcare Research and Quality (AHRQ)	Improving cultural competence to reduce health disparities
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Autologous haematopoietic stem cell transplantation - multiple sclerosis: relapsing remitting – second line
2016	National Institute for Health and Care Excellence (NICE)	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 411
2016	Agency for Healthcare Research and Quality (AHRQ)	Early diagnosis, prevention, and treatment of Clostridium difficile: update
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Low dose desmopressin acetate (Noqdirna) - nocturia: idiopathic nocturnal polyuria; symptomatic; in adults – as sole agent or as a combination treatment
2016	National Institute for Health and Care Excellence (NICE)	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. NICE technology appraisal guidance 412
2016	NIHR Health Technology Assessment programme	An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Data linkage strategies to advance youth suicide prevention
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dupilumab - atopic dermatitis: moderate to severe; inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable – second line
2016	National Institute for Health and Care Excellence (NICE)	Elbasvirgrazoprevir for treating chronic hepatitis C. NICE technology appraisal guidance 413
2016	NIHR Health Technology Assessment programme	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
2016	Agency for Healthcare Research and Quality (AHRQ)	Nonpharmacologic interventions for agitation and aggression in dementia
2016	National Institute for Health and Care Excellence (NICE)	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 414
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatments for fecal incontinence
2016	National Institute for Health and Care Excellence (NICE)	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor. NICE technology appraisal guidance 415
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for patients with lower extremity chronic venous disease (LECVD)
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 417
2016	NIHR Health Technology Assessment programme	The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: a multicentre randomised controlled trial and health-economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Retinal prostheses in the Medicare population
2016	National Institute for Health and Care Excellence (NICE)	Dapagliflozin in triple therapy for treating type 2 diabetes. NICE technology appraisal guidance 418
2016	Agency for Healthcare Research and Quality (AHRQ)	Renal denervation in the Medicare Population
2016	National Institute for Health and Care Excellence (NICE)	Apremilast for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 419
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson s disease: a large pragmatic randomised controlled trial (PD REHAB)
2016	NIHR Health Technology Assessment programme	Tackling obesity in areas of high social deprivation: clinical effectiveness and cost-effectiveness of a task-based weight management group programme a randomised controlled trial and economic evaluation
2016	NIHR Health Technology Assessment programme	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
2016	NIHR Health Technology Assessment programme	Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation
2016	National Institute for Health and Care Excellence (NICE)	Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420
2016	NIHR Health Technology Assessment programme	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study
2016	NIHR Health Technology Assessment programme	The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation
2016	National Institute for Health and Care Excellence (NICE)	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 421
2016	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES)
2016	NIHR Health Technology Assessment programme	Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016	NIHR Health Technology Assessment programme	Orthotic management of instability of the knee related to neuromuscular and central nervous system disorders: systematic review, qualitative study, survey and costing analysis
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine sSystem (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. NICE technology appraisal guidance 423
2016	NIHR Health Technology Assessment programme	The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis
2016	NIHR Public Health Research (PHR) programme	Implications for public health research of models and theories of disability: a scoping study and evidence synthesis
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer. NICE technology appraisal guidance 424
2016	NIHR Health Technology Assessment programme	A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services: the Northern Ireland Caries Prevention In Practice (NIC-PIP) trial
2016	NIHR Health Technology Assessment programme	Social Stories to alleviate challenging behaviour and social difficulties exhibited by children with autism spectrum disorder in mainstream schools: design of a manualised training toolkit and feasibility study for a cluster randomised controlled trial with nested qualitative and cost-effectiveness components
2016	NIHR Health Technology Assessment programme	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation
2016	NIHR Health Services and Delivery Research programme	Do-not-attempt-cardiopulmonary-resuscitation decisions: an evidence synthesis
2016	NIHR Health Services and Delivery Research programme	The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. NICE technology appraisal guidance 425
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Everolimus (Afinitor) for diffuse large B-cell lymphoma – maintenance therapy
2016	NIHR Health Services and Delivery Research programme	Determining the optimal model for role substitution in NHS dental services in the UK: a mixed-methods study
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. NICE technology appraisal guidance 426
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer
2016	Adelaide Health Technology Assessment (AHTA)	Microwave tissue ablation for primary and secondary liver cancer
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: OHTAC Recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	ADI-PEG 20 for hepatocellular carcinoma – second line
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: OHTAC recommendation
2016	NIHR Health Technology Assessment programme	An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft
2016	NIHR Public Health Research (PHR) programme	IMPRoving Outcomes for children exposed to domestic ViolencE (IMPROVE): an evidence synthesis
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Furosemide sc2Wear micro-pump patch for oedema in heart failure
2016	NIHR Health Services and Delivery Research programme	Getting the most out of knowledge and innovation transfer agents in health care: a qualitative study
2016	NIHR Health Technology Assessment programme	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy
2016	NIHR Health Services and Delivery Research programme	Location of care for people with serious mental illness (LOCAPE): implications for service use and costs using a mixed-methods approach
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Remestemcel-L for graft vs host disease in paediatric patients – second line